Published in

Karger Publishers, Case Reports in Ophthalmology, 3(4), p. 279-282, 2013

DOI: 10.1159/000357060

Links

Tools

Export citation

Search in Google Scholar

Uveitis as a Result of MAP Kinase Pathway Inhibition

Journal article published in 2013 by Lavnish Joshi, Andreas Karydis, Maria Gemenetzi, Emily H. Shao, Simon R. J. Taylor ORCID
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Green circle
Published version: archiving allowed
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

We report the case of a patient treated with dabrafenib and trametinib (mitogen-activated protein kinase pathway inhibitors) for stage 3b cutaneous melanoma who developed bilateral uveitis. Although there have been reports of ocular side effects with this class of drugs, uveitis has not been previously reported to the best of our knowledge. This case indicates the wide range of side effects that can be seen with the newer targeted biological therapies.